COX-2 inhibition with rofecoxib does not increase intestinal permeability in healthy subjects: A double blind crossover study comparing rofecoxib with placebo and indomethacin

Gut

Volumn 47, Issue 4, 2000, Pages 527-532

  Sigthorsson, G ^a   Crane, R ^a   Simon, T ^b   Hoover, M ^b   Quan, H ^b   Bolognese, J ^b   Bjarnason, I ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

COX 2 inhibitor; Indomethacin; Intestinal permeability; Non steroidal anti inflammatory drugs; Osteoarthritis; Rofecoxib

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; EDETATE CHROMIUM CR 51; INDOMETACIN; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; RHAMNOSE; ROFECOXIB;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; HUMAN EXPERIMENT; INTESTINE MUCOSA PERMEABILITY; MALE; NORMAL HUMAN; OSTEOARTHRITIS; PRIORITY JOURNAL;

ADOLESCENT; ADULT; CHROMIUM RADIOISOTOPES; CROSS-OVER STUDIES; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DOUBLE-BLIND METHOD; EDETIC ACID; FEMALE; HUMANS; INDOMETHACIN; INTESTINAL MUCOSA; ISOENZYMES; LACTONES; MALE; MEMBRANE PROTEINS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; SULFONES;

EID: 0033799852     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.47.4.527     Document Type: Article

References (34)

1. 1 Cryer B. Nonsteroidal anti-inflammatory drugs and gastrointestinal disease. In: Feldman M, Scharschmidt BF, Sleisenger MH, eds. Sleisenger and Fordtran's gastrointestinal and liver disease, 6th edn. Philadelphia: Saunders, 1998:343-57.
2. 2 Bjarnason I, Williams P, So A, et al. Intestinal permeability and inflammation in rheumatoid arthritis: effects of non-steroidal anti-inflammatory drugs. Lancet 1984;2: 1171-4.
3. 3 Segal AW, Isenberg DA, Hajirousou V, et al. Preliminary evidence for gut involvement in the pathogenesis of rheumatoid arthritis? Br J Rheumatol 1986;25:162-6.
4. 4 Bjarnason I, Zanelli G, Smith T, et al. Nonsteroidal anti-inflammatory drug-induced intestinal inflammation in humans. Gastroenterology 1987;93:480-9.
5. 5 Bjarnason I, Zanelli G, Prouse P, et al. Blood and protein loss via small-intestinal inflammation induced by non-steroidal anti-inflammatory drugs. Lancet 1987;2:711-14.
6. 6 Bj́arnason I, Price AB, Zanelli G, et al. Clinicopathological features of nonsteroidal antiinflammatory drug-induced small intestinal strictures. Gastroenterology 1988;94:1070-4.
7. 7 Bjarnason I, Zanelli G, Smith T, et al. The pathogenesis and consequence of non steroidal anti-inflammatory drug induced small intestinal inflammation in man. Scand J Rheumatol Suppl 1987;64(suppl 69):55-62.
8. 8 Bjarnason I, Fehilly B, Smethurst P, et al. Importance of local versus systemic effects of non-steroidal anti-inflammatory drugs in increasing small intestinal permeability in man. Gut 1991;32:275-7.
9. 9 Bjarnason I, Hayllar J, Macpherson AJ, et al. Side effects of nonsteroidal anti-inflammatory drugs on the small and large intestine in humans. Gastroenterology 1993;104:1832-47.
10. 10 Somasundaram S, Hayllar H, Rafi S, et al. The biochemical basis of non-steroidal anti-inflammatory drug-induced damage to the gastrointestinal tract: a review and a hypothesis. Scand J Gastroenterol 1995;30:289-99.
11. 11 Mahmud T, Rafi SS, Scott DL, et al. Nonsteroidal antiinflammatory drugs and uncoupling of mitochondrial oxidative phosphorylation. Arthritis Rheum 1996;39:1998-2003.
12. 12 Bjarnason I, Smethurst P, Fenn CG, et al. Misoprostol reduces indomethacin-induced changes in human small intestinal permeability. Dig Dis Sci 1989;34:407-11.
13. 13 Bjarnason I, Williams P, Smethurst P, et al. Effect of non-steroidal anti-inflammatory drugs and prostaglandins on the permeability of the human small intestine. Gut 1986;27:1292-7.
14. 14 Meade EA, Smith WL, DeWitt DL. Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal antiinflammatory drugs. J Biol Chem 1993;268:6610-14.
15. 15 Fosslien E. Adverse effects of nonsteroidal antiinflammatory drugs on the gastrointestinal system. Ann Clin Lab Sci 1998;28:67-81.
16. 16 Mitchell JA, Akarasereenont P, Thiemermann C, et al. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci USA 1993;90:11693-7.
17. 17 Enrich E, Schnitzer T, Kivitz A, et al. MK-966, a highly selective COX-2 inhibitor, was effective in the treatment of osteoarthritis (OA) of the knee and hip in a 6-week placebo controlled study. Arthritis Rheum 1999;40:S85.
18. 18 Saag K, Fisher C, McKay J, et al. MK-0966, a specific COX-2 inhibitor has clinical efficacy comparable to ibuprofen in the treatment of knee and hip osteoarthritis (OA) in a 6-week controlled clinical trial. Arthritis Rheum 1998;41:S196.
19. 19 Warner TD, Giuliano F, Vojnovic I, et al. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci USA 1999;96:7563-8.
20. 20 Chan CC, Boyce S, Brideau C, et al. Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles. J Pharmacol Exp Ther 1999;290:551-60.
21. 21 Enrich EW, Dallob A, De L I, et al. Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model. Clin Pharmacol Ther 1999;65:336-47.
22. 22 Cryer B, Gottesdiener K, Gertz B, et al. Effects of a novel cyclooxygenase (COX)-2 inhibitor on gastric mucosal prostaglandin (PG) synthesis in healthy humans. Am J Gastroenterol 1998;91:1907.
23. 23 Lanza FL, Simon T, Quan H, et al. Selective inhibition of cyclooxygenase-2 (COX-2) with MK-0966 (250 mg Q.D.) is associated with less gastroduodenal damage than aspirin (ASA) 650 mg Q.I.D. or ibuprofen (IBU) 800 mg T.I.D. Gastroenterolgy 1998;112:A194.
24. 24 Hunt R, Bowen B, James C, et al. COX-2 specific inhibition with MK-0966 25 or 50 mg Q.D. over 4 weeks does not increase fecal blood loss. A controlled study with placebo and ibuprofen 800 mg T.I.D. Am J Gastroenterol 1998;93: 1671.
25. 25 Bjarnason I, Macpherson A, Hollander D. Intestinal permeability: an overview. Gastroenterology 1995;108:1566-81.
26. 26 Bjarnason I, Maxton D, Reynolds AP, et al. Comparison of four markers of intestinal permeability in control subjects and patients with coeliac disease. Scand J Gastroenterol 1994;29:630-9.
27. 27 Kendall MJ, Nutter S, Hawkins CF. Xylose test: effect of aspirin and indomethacin. BMJ 1971;1:533-6.
28. 28 Dyer NH, Kendall MJ, Hawkins CF. Malabsorption in rheumatoid disease. Ann Rheum Dis 1971;30:626-30.
29. 29 Menzies IS, Mount JN, Wheeler MJ. Quantitative estimation of clinically important monosaccharides in plasma by rapid thin layer chromatography. Ann Clin Biochem 1978;15:65-76.
30. 30 Laine L, Hawkey C, Harper SE, et al. Effect of the COX-2 specific inhibitor (C-2SI), rofecoxib, on ulcer formation: A double-blind comparison with ibuprofen and placebo. Gastroenterology 1999;116:A229.
31. 31 Lanza FL, Rack MF, Simon TJ. et al. Specific inhibition of cyclooxygenase-2 with MK-0966 is associated with less gastroduodenal damage than either aspirin or ibuprofen. Aliment Pharmacol Ther 1999;13:761-7.
32. 32 Sigthorsson G, Tibble J, Hayllar J, et al. Intestinal permeability and inflammation in patients on NSAIDs. Gut 1998;43:506-11.
33. 33 Bjarnason I, Smethurst P, Clark P, et al. Effect of prostaglandin on indomethacin-induced increased intestinal permeability in man. Scand J Gastroenterol 1989; 164(suppl 146):97-102.
34. 34 Bjarnason I, Zanelli G, Smith T, et al. Nonsteroidal antiinflammatory drug-induced intestinal inflammation in humans. Gastroenterology 1987;93:480-9.